Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").

Porton will provide comprehensive CDMO services for Aojin in the CMC pharmaceutical research and GMP production of XDC conjugate drugs, targeting dual IND filings in China and the United States. Leveraging nearly two decades of end-to-end integrated CDMO service experiences, Porton has assembled a multidisciplinary project team that bridges drug substance and drug product technologies, integrating expertise in both small and large molecules. This strategic collaboration marks the beginning of a comprehensive and in-depth partnership between Porton and Aojin in the XDC conjugate drug sector.

Together, we aim to promote the vigorous development of global XDC conjugate drugs, enabling the public's early access to good medicines.